(ORIC) Oric Pharmaceuticals - Ratings and Ratios
ORIC-114, ORIC-944, ORIC-533, ORIC-613
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 69.6% |
| Value at Risk 5%th | 106% |
| Relative Tail Risk | -7.47% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.37 |
| Alpha | -20.24 |
| CAGR/Max DD | 0.23 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.531 |
| Beta | 1.341 |
| Beta Downside | 1.294 |
| Drawdowns 3y | |
|---|---|
| Max DD | 73.46% |
| Mean DD | 30.48% |
| Median DD | 32.61% |
Description: ORIC Oric Pharmaceuticals November 18, 2025
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) is a clinical-stage biopharma focused on developing small-molecule therapies that overcome resistance mechanisms in oncology, primarily within the United States.
Its lead candidates are ORIC-114, an orally bioavailable irreversible inhibitor that penetrates the brain and selectively targets EGFR and HER2 exon 20 insertion mutations (currently in a Phase 1b trial), and ORIC-944, an allosteric PRC2 inhibitor being evaluated for prostate cancer (also in Phase 1b). Additional programs include ORIC-533 (a CD73 inhibitor) and ORIC-613 (targeting innate resistance in a subset of breast cancers).
The company has secured development collaborations with major pharma partners: a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer; a trial and supply agreement with Bayer to test ORIC-944 alongside the AR inhibitor Nubeqa; and a similar agreement with Johnson & Johnson to combine ORIC-944 with Erleada. As of the latest 10-Q, ORIC reported a cash runway of roughly 12 months and a market capitalization near $150 million, reflecting the typical valuation range for early-stage oncology players.
Sector-wide, the EGFR exon 20 insertion market is projected to exceed $1 billion by 2028, driven by limited treatment options and rising prevalence of targeted sequencing; meanwhile, PRC2 inhibition is gaining traction after recent positive data in epigenetic oncology. Investors should watch cash burn trends, upcoming data readouts (expected Q1 2026 for ORIC-114), and the likelihood of milestone payments from the Pfizer, Bayer, and J&J collaborations. For a deeper, data-driven assessment of ORIC’s risk-adjusted upside, consider exploring the analyst tools on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-135.3m TTM) > 0 and > 6% of Revenue (6% = 64.0k TTM) |
| FCFTA -0.27 (>2.0%) and ΔFCFTA 9.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 25.8k% (prev 16.8k%; Δ 9050 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.27 (>3.0%) and CFO -116.8m > Net Income -135.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 14.65 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (99.0m) change vs 12m ago 40.27% (target <= -2.0% for YES) |
| Gross Margin 14.07% (prev 30.69%; Δ -16.62pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.29% (prev 0.51%; Δ -0.22pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -26.02 (EBITDA TTM -139.5m / Interest Expense TTM -5.41m) >= 6 (WARN >= 3) |
Altman Z'' -31.99
| (A) 0.64 = (Total Current Assets 295.6m - Total Current Liabilities 20.2m) / Total Assets 431.2m |
| (B) -1.53 = Retained Earnings (Balance) -661.7m / Total Assets 431.2m |
| warn (B) unusual magnitude: -1.53 — check mapping/units |
| (C) -0.38 = EBIT TTM -140.7m / Avg Total Assets 366.6m |
| (D) -27.24 = Book Value of Equity -661.1m / Total Liabilities 24.3m |
| Total Rating: -31.99 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 35.02
| 1. Piotroski 0.0pt |
| 2. FCF Yield -19.44% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.01 |
| 5. Debt/Ebitda 0.33 |
| 6. ROIC - WACC (= -48.16)% |
| 7. RoE -45.33% |
| 8. Rev. Trend 18.10% |
| 9. EPS Trend 74.88% |
What is the price of ORIC shares?
Over the past week, the price has changed by +2.55%, over one month by -28.50%, over three months by -19.41% and over the past year by +2.93%.
Is ORIC a buy, sell or hold?
- Strong Buy: 10
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ORIC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 20.8 | 147.1% |
| Analysts Target Price | 20.8 | 147.1% |
| ValueRay Target Price | 8.3 | -2.1% |
ORIC Fundamental Data Overview December 18, 2025
P/B = 2.209
Beta = 1.318
Revenue TTM = 1.07m USD
EBIT TTM = -140.7m USD
EBITDA TTM = -139.5m USD
Long Term Debt = 3.30m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.30m USD (from shortTermDebt, last quarter)
Debt = 3.30m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -46.4m USD (from netDebt column, last quarter)
Enterprise Value = 604.4m USD (888.2m + Debt 3.30m - CCE 287.1m)
Interest Coverage Ratio = -26.02 (Ebit TTM -140.7m / Interest Expense TTM -5.41m)
FCF Yield = -19.44% (FCF TTM -117.5m / Enterprise Value 604.4m)
FCF Margin = -11.0k% (FCF TTM -117.5m / Revenue TTM 1.07m)
Net Margin = -12.7k% (Net Income TTM -135.3m / Revenue TTM 1.07m)
Gross Margin = 14.07% ((Revenue TTM 1.07m - Cost of Revenue TTM 916.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.40 (Enterprise Value 604.4m / Total Assets 431.2m)
Interest Expense / Debt = 60.16% (Interest Expense 1.99m / Debt 3.30m)
Taxrate = 21.0% (US default 21%)
NOPAT = -111.1m (EBIT -140.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 14.65 (Total Current Assets 295.6m / Total Current Liabilities 20.2m)
Debt / Equity = 0.01 (Debt 3.30m / totalStockholderEquity, last quarter 406.9m)
Debt / EBITDA = 0.33 (negative EBITDA) (Net Debt -46.4m / EBITDA -139.5m)
Debt / FCF = 0.39 (negative FCF - burning cash) (Net Debt -46.4m / FCF TTM -117.5m)
Total Stockholder Equity = 298.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.37% (Net Income -135.3m / Total Assets 431.2m)
RoE = -45.33% (Net Income TTM -135.3m / Total Stockholder Equity 298.4m)
RoCE = -46.62% (EBIT -140.7m / Capital Employed (Equity 298.4m + L.T.Debt 3.30m))
RoIC = -37.24% (negative operating profit) (NOPAT -111.1m / Invested Capital 298.4m)
WACC = 10.92% (E(888.2m)/V(891.5m) * Re(10.96%) + (debt cost/tax rate unavailable))
Discount Rate = 10.96% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 31.23%
Fair Price DCF = unknown (Cash Flow -117.5m)
EPS Correlation: 74.88 | EPS CAGR: 39.80% | SUE: 2.01 | # QB: 1
Revenue Correlation: 18.10 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.38 | Chg30d=+0.022 | Revisions Net=+2 | Analysts=8
EPS next Year (2026-12-31): EPS=-1.57 | Chg30d=+0.140 | Revisions Net=+4 | Growth EPS=+3.6% | Growth Revenue=+0.0%
Additional Sources for ORIC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle